AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
WuXi Biologics (Cayman) Inc.
Video analysis: WXXWY
All videosNo video analysis for this stock yet. Request one from our team.
News: WXXWY
WuXi Biologics (Cayman) Inc. (WXXWY) Q2 2026 Earnings Call Transcript
WuXi Biologics (Cayman) Inc. (WXXWY) Q2 2026 Earnings Call Transcript
WuXi Biologics (Cayman) Inc. (OTCMKTS:WXXWY) Short Interest Down 81.8% in July
WuXi Biologics (Cayman) Inc. (OTCMKTS:WXXWY - Get Free Report) was the recipient of a significant drop in short interest during the month of July. As of July 31st, there was short interest totaling 46,353 shares, a drop of 81.8% from the July 15th total of 255,103 shares. Based on an average daily volume of 113,253
WuXi Biologics' 25th Drug Substance Facility Completes First GMP Production, Manufacturing Process Execution with Zero Deviations
SHANGHAI, June 24, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that its MFG17 drug substance facility located at the Shanghai Fengxian site has successfully completed its first GMP production campaign. The manufacturing process execution was completed with zero deviations, while critical process parameters remained stable and yields reached expected levels, demonstrating robust process performance and strong execution capabilities.
WuXi Biologics' Suzhou Biosafety Testing Center Received Fourth EMA GMP Certification, Enabling 19 Commercial Products for the European Market
SUZHOU, China, June 18, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that its Biosafety Testing Center in Suzhou has successfully passed a Good Manufacturing Practice (GMP) inspection by the European Medicines Agency (EMA) with zero critical findings. This marks the fourth time the facility has successfully received EMA GMP certificate.
Similar companies
-
Inhibikase Therapeutics, Inc.
IKT
·
NASDAQ
Compare
-
Corcept Therapeutics Incorporated
CORT
·
NASDAQ
Compare
-
Cardio Diagnostics Holdings, Inc.
CDIO
·
NASDAQ
Compare
-
Revolution Medicines, Inc.
RVMD
·
NASDAQ
Compare
-
Syndax Pharmaceuticals, Inc.
SNDX
·
NASDAQ
Compare
-
Panbela Therapeutics, Inc.
PBLA
·
Other OTC
Compare